证券之星消息，12月5日动物保健板块较上一交易日上涨1.45%，生物股份领涨。当日上证指数报收于 3902.81，上涨0.7%。深证成指报收于13147.68，上涨1.08%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 36.64 | -0.57% | 3.37万 | 1.22亿 | | 300119 | 瑞普生物 | 19.23 | -0.21% | 4.17万 | 8014.54万 | | 920275 | 驱动力 | 8.93 | 0.00% | 2.17万 | 1895.31万 | | 688526 | 科前生物 | 15.55 | 0.32% | 1.20万 | 1862.15万 | | 603566 | 普莱柯 | 13.08 | 0.46% | 2.52万 | 3283.78万 | | 002141 | 贤丰控股 | 3.94 | 0.51% | 21.89万 | 8580.68万 | | 688098 | 申联生 ...

Core Viewpoint - The company, Pulaike, plans to acquire a 4.04% stake in Zhongpu Biological from CITIC Agriculture, which will make Pulaike the controlling shareholder of Zhongpu Biological, a company currently facing continuous losses in the production of foot-and-mouth disease vaccines [1][9]. Company Overview - Zhongpu Biological, formerly known as Baoshan Biological Pharmaceutical Factory, specializes in the research, production, and technical services of foot-and-mouth disease vaccines. It has been in a loss-making state due to declining industry conditions and overcapacity [1][10]. - Pulaike currently holds a 46.97% stake in Zhongpu Biological, while CITIC Agriculture holds 4.04%. After the acquisition, Pulaike's stake will increase to 51.01%, surpassing the current largest shareholder, Zhongmu Co., Ltd. [1][10]. Financial Performance - Zhongpu Biological is projected to generate revenue of 37.01 million yuan in 2024, with a loss of 26.21 million yuan. In the first half of 2025, it is expected to achieve revenue of 18.85 million yuan, with a loss of 18.24 million yuan [2][10]. - Pulaike's revenue for 2024 is expected to decline by 16.77% to 1.043 billion yuan, with a net profit drop of 46.82% to 92.81 million yuan. The gross margin has decreased by 4.32 percentage points, and the net margin has fallen by 13.32 percentage points to 8.9% [4][13]. Industry Challenges - The animal health industry is facing challenges due to a decline in market conditions and overcapacity, with the number of manufacturers producing foot-and-mouth disease vaccines increasing from 7 to 10, leading to an estimated total capacity exceeding 13 billion milliliters per year [2][11]. - The utilization rate of vaccine manufacturers is low, with some companies reporting as low as 20.83% utilization [2][11]. Operational Issues - Pulaike's core business of pig vaccines has been under pressure, with revenue from this segment declining by 22.6% to 336 million yuan in 2024, despite having a gross margin of 83.89% [4][13]. - The company has invested heavily in new production facilities, resulting in a significant increase in depreciation expenses, which rose by 20.65% in 2024 [5][14]. Recent Developments - In the first three quarters of the year, Pulaike's revenue grew by 8.04% to 823 million yuan, and net profit increased by 47.86% to 157 million yuan. However, the growth in net profit is attributed to cost-cutting measures rather than revenue growth [6][15]. - Despite some recovery in new business segments, the overall revenue has started to decline, with a 5.39% drop in the third quarter [7][16]. Accounts Receivable Concerns - As of the end of the third quarter, Pulaike's accounts receivable reached 335 million yuan, accounting for 41% of its revenue, indicating potential cash flow issues [7][16].

Investment Rating - The report rates the pet nutrition industry as a high-growth sector with a compound annual growth rate (CAGR) of 28.3% from 2020 to 2024, expected to continue growing at a CAGR of 14.21% from 2025 to 2029 [5][41]. Core Insights - The pet nutrition industry is experiencing rapid growth driven by increasing pet ownership, changing consumer attitudes towards pet care, and a shift towards premium, functional products. The market size is projected to grow from 31 billion RMB in 2020 to 84 billion RMB in 2024, and further to 164.7 billion RMB by 2029 [5][41]. - The industry is characterized by product functionalization and segmentation, the rise of domestic brands, and diversified sales channels, particularly online [5][10][13]. Summary by Sections Industry Definition - The pet nutrition industry focuses on developing and selling nutritional supplements tailored to pets' various life stages and physiological needs, including products like pastes, fish oil, probiotics, and vitamins [6]. Industry Characteristics - The industry is moving from basic nutrition to functional and segmented products, with a strong preference for gastrointestinal and immune-boosting products [11]. - Domestic brands have gained significant market share, accounting for 61% of the market by 2024, surpassing foreign brands [12]. - Sales channels have diversified, with e-commerce platforms dominating, accounting for 50% of sales [13]. Development History - The industry has evolved through three stages: initial awareness (2001-2010), rapid growth (2011-2020), and maturity with diversification (2021-present) [14][16]. Industry Chain Analysis - The industry chain consists of upstream raw material suppliers, midstream brand manufacturers, and downstream sales channels [17]. - Upstream suppliers are increasingly focusing on quality and innovation in response to consumer demands for safety and transparency [23][24]. Market Dynamics - The pet nutrition market reached 84 billion RMB in 2024, with a CAGR of 28.3% from 2020 to 2024, indicating strong demand [19][37]. - The leading brand, RedDog, dominates the market with significant sales in key segments, reflecting a concentrated competitive landscape [21][40][56]. Future Growth Trends - The market is expected to grow to 185.9 billion RMB by 2030, with a CAGR of 13.9% from 2025 to 2030, driven by consumer demand for high-quality, functional products [47][49]. - The pet paste market is projected to reach 50.7 billion RMB by 2030, with significant growth in specific categories like hairball pastes and fish oil [45][49].

Core Viewpoint - The animal health sector experienced a decline of 0.7% on December 2, with Shenyuan Biological leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1][2]. Stock Performance Summary - The closing prices and performance of key stocks in the animal health sector are as follows: - Shenyuan Biological (688088) closed at 9.28, down 2.93% with a trading volume of 40,900 shares and a turnover of 38.24 million yuan [2]. - Shengong Holdings (002141) closed at 4.13, down 0.96% with a trading volume of 387,200 shares and a turnover of 159 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 12.45, up 1.63% [1]. - Zhongmu Shares (600195) at 7.64, down 0.26% [1]. - Jinhai Biological (002688) at 6.17, down 0.32% [1]. Capital Flow Analysis - The animal health sector saw a net outflow of 10.78 million yuan from institutional investors, while retail investors had a net inflow of 16.68 million yuan [2][3]. - Key capital flow details include: - Shengong Holdings had a net inflow of 8.69 million yuan from institutional investors [3]. - ST Green Kang (002868) experienced a net inflow of 5.73 million yuan from institutional investors [3]. - Other stocks like Hailey Biological (603718) and Jinhai Biological (002688) showed mixed capital flows with varying net inflows and outflows [3].

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

从资金流向上来看，当日动物保健板块主力资金净流出4892.47万元，游资资金净流入2685.5万元，散户 资金净流入2206.97万元。动物保健板块个股资金流向见下表： 证券之星消息，11月28日动物保健板块较上一交易日下跌0.56%，*ST绿康领跌。当日上证指数报收于 3888.6，上涨0.34%。深证成指报收于12984.08，上涨0.85%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920729 | 永顺生物 | 9.07 | 1.57% | 1.29万 | ly 1155.04万 | | | 920275 | 驱动力 | 9.32 | 0.76% | 5832.76 | 537.20万 | | | 600201 | 生物股份 | 12.22 | 0.58% | 16.68万 | | 2.04亿 | | 600195 | 中牧股份 | 7.77 | 0.39% | 6.59万 | 5095.91万 | | | 920970 | 大禹生物 ...

农林牧渔行业 超配（维持） 农林牧渔行业双周报（2025/11/14-2025/11/27） 行 业 牧原股份赴港上市获证监会备案 2025 年 11 月 28 日 投资要点： 风险提示：疫病大规模爆发，价格下行，自然灾害，市场竞争加剧等。 资料来源：iFinD ，东莞证券研究 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 分析师：魏红梅 SAC 执业证书编号： S0340513040002 电话：0769-22119462 邮箱：whm2@dgzq.com.cn SW农林牧渔行业略跑赢沪深300指数。2025年11月14日—2025年11月27日， SW农林牧渔行业下跌3.79%，跑赢同期沪深300指数约0.18个百分点；细分 板块中，仅渔业录得正收益，上涨7.89%；动物保健、种植业、养殖业、 饲料和农产品加工均录得负收益，分别下跌0.85%、3.31%、3.34%、4.76% 和7.96%。估值方面，截至2025年11月27日，SW农林牧渔行业指数整体PB （整体法，最新报告期，剔除负值）约2.80倍 ...

Core Viewpoint - The company, Jinyu Biotechnology Co., Ltd., reported a revenue of 1.04 billion yuan in the first three quarters of 2023, reflecting a year-on-year growth of 7.38%, and a net profit of 161 million yuan [2]. Group 1: Financial Performance - In Q3 2023, the company achieved a revenue of 423 million yuan, representing a year-on-year increase of 17.76%, and a net profit of 101 million yuan, which is a significant growth of 116.40% [3]. - For the first three quarters of 2023, the company's R&D expenses amounted to 96.01 million yuan, showing a year-on-year increase of 9.08% [4]. Group 2: Product and Market Strategy - The company focuses on the research, production, and sales of veterinary biological products, with a product range that includes over a hundred types of vaccines for pigs, poultry, ruminants, and pets [3]. - The company is implementing a "big product, big customer" strategy, achieving breakthroughs in the development of major vaccines such as foot-and-mouth disease, African swine fever, and feline infectious peritonitis [3]. - The company is expanding its international presence, with products registered and sold in countries like Pakistan and Vietnam, and plans to enhance penetration in Central Asia, Southeast Asia, and Africa [4]. Group 3: Innovation and Future Plans - The company emphasizes technological innovation to address industry challenges, with ongoing development of innovative products like the African swine fever subunit vaccine and mRNA vaccine for feline infectious peritonitis [3]. - The company aims to transition from single product sales to a model that includes "professional services + comprehensive solutions," focusing on deep customer engagement [5]. - The pet business is identified as a significant growth area, with plans to establish a pet marketing ecosystem and expand into health products and pharmaceuticals [5].

Core Viewpoint - The company, Reap Bio (300119.SZ), currently does not have a specific vaccine for the H5N5 avian influenza, but its existing H5+H7 vaccine theoretically offers good protection against the prevalent H5N5 strain due to its genetic components [1] Group 1 - The company and the domestic market currently lack a dedicated H5N5 avian influenza vaccine [1] - The H5N5 strain circulating abroad belongs to the clade 2.3.4.4b genetic branch, which is crucial for evaluating vaccine efficacy [1] - The existing H5+H7 vaccine contains components of the clade 2.3.4.4b strain, suggesting it can provide adequate protection [1]

Core Viewpoint - The company is actively expanding its pet health product line, with a long-term product planning scheme that includes chemical drugs, biological products, and pet health products [1] Group 1: Product Development - The company is focusing on self-branded production and sales of pet health products, without engaging in OEM business [1] - A comprehensive R&D and market operation team will be gradually established to support product promotion [1] Group 2: Market Strategy - The company plans to develop distribution channels primarily through offline veterinary hospitals [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations, ensuring timely announcements of relevant information [1]